Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
February 25, 2025Pamplona/MadridIn recruitment
IELSG48 Phase 3 clinical trial comparing rituximab plus zanubrutinib with rituximab monotherapy in previously untreated symptomatic splenic marginal zone lymphoma
The aim of this clinical trial is to compare the efficacy and tolerability of the combination of two drugs, rituximab and zanubrutinib, compared to rituximab monotherapy in patients with previously untreated splenic marginal zone lymphoma (SMZL) requiring systemic treatment. -
February 25, 2025PamplonaIn recruitment
GCT1078-01 Clinical trial of GEN1078 in participants with malignant solid tumors.
The aim of this study is to find out if the trial drug is safe in participants with certain types of cancer and to find out what is the best dose. -
February 24, 2025Pamplona/MadridIn recruitment
D7020C00001 Clinical trial of the anti-TIGIT/anti-PD-1 bispecific antibody AZD2936 in patients with advanced or metastatic non-small cell lung cancer.
The objective of this study is to learn more about AZD2936, a new antibody that blocks two proteins (PD-1 and TIGIT) at the same time. AZD2936 can be used if unresectable or metastatic non-small cell lung cancer has been diagnosed. The main objective of this study is to gather information on the correct dose of AZD2936 and to understand whether this new drug can be useful for the treatment of the diagnosed disease. Both PD-1 and TIGIT are called "immune checkpoints". They emit signals ... -
February 18, 2025Pamplona/MadridIn recruitment
D8470C00001 Phase I/IIa clinical trial to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AZD8421 alone or in combination in patients with selected advanced or metastatic solid tumors (CYCAD-1)
El objetivo es investigar la seguridad y tolerabilidad, caracterizar los DLT y determinar la DMT y/o DMF y/o dosis recomendada dosis recomendada de fase II (RP2D) de AZD8421 como monoterapia y también en combinación con otros medicamentos contra el cáncer. -
February 18, 2025Pamplona/MadridIn recruitment
SLN124-004 Phase I/II clinical trial of SLN124 in patients with polycythemia vera with an open-label dose-escalation phase followed by a randomized double-blind phase.
The main objective is to evaluate the safety and tolerability of single and multiple subcutaneous (s.c.) doses of SLN124 in patients with polycythemia vera (PV). -
February 18, 2025PamplonaIn recruitment
IVY-P3-24-021 Phase III, open-label, randomized, 2-group clinical trial to compare the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly diagnosed MGMT-unmethylated glioblastoma
This is a Phase III trial. This trial includes: Phase 1, in which the trial drug or comparator drug will be taken and all participants will also receive radiotherapy; and Phase 2, in which they will continue with the same drug they were given in Phase 1 without radiotherapy. -
February 18, 2025Pamplona/MadridIn recruitment
EF-44 [SP]
The aim of this study is to evaluate the efficacy and safety of TTFields together with the reference treatment, pembrolizumab and platinum-derived chemotherapy. -
February 10, 2025PamplonaIn recruitmentEarly phase
FS222-19101 Trial to evaluate the safety and antitumor activity of FS222, a bispecific antibody against CD137/PD-L1, in subjects with advanced malignancies.
The aim is to determine whether FS222 is safe in the treatment of cancer and the degree to which a person tolerates the side effects. -
February 10, 2025Pamplona/MadridIn recruitmentEarly phase
CA119-0002 Clinical Trial of BMS-986453, chimeric antigenic receptor (CAR) T-lymphocytes with dual targeting of BCMAxGPRC5D in subjects with relapsed or refractory multiple myeloma.
The aim of this study is to assess whether BMS-986453 is safe and effective for treating people whose multiple myeloma (MM) has recurred after previous treatment (relapsed) or who have MM that is not responding to current treatment (refractory). -
February 5, 2025PamplonaIn recruitment
MCLA-158-CL03 Ensayo clínico para evaluar la eficacia y la seguridad de petosemtamab más pembrolizumab frente a pembrolizumab en el tratamiento de primera línea del carcinoma epidermoide de cabeza y cuello PD-L1 recurrente o metastásico [SP]
Los objetivos de este estudio son determinar los posibles efectos secundarios del fármaco delestudio cuando se utiliza en combinación con otro fármaco ya aprobado llamado pembrolizumab; si el fármaco del estudio puede detener o no la progresión del cáncer epidermoide de cabeza y cuello en el organismo; si puede mejorar o no las posibilidades de supervivencia; cómo procesa su organismo el fármaco del estudio más el pembrolizumab en comparación con el pembrolizumab por sí solo; si puede mejorar o ...